FDA Grants 510(k) Clearance to BrainSpace's Intellidrop Automated Brain Fluid Management System
Key Insights
The U.S. FDA has granted 510(k) clearance to BrainSpace (search)'s Intellidrop (search), an automated brain fluid management system that provides continuous brain pressure measurement and precision drainage of cerebrospinal fluid (search).
The device is indicated for external drainage of CSF and monitoring of intracranial pressure (search) for patients with traumatic brain injury (search), stroke (search), skull base tumor (search) surgeries, and neurodegenerative conditions.
According to a recent Lancet study, 1 in 3 people globally will face neuro injury, illness or degeneration in their lifetime, representing 2.5 billion people who could benefit from improved neurological care.
BrainSpace (search), a medical technology company focused on automated solutions for neurological conditions, has received U.S. Food and Drug Administration (search) 510(k) clearance for its Intellidrop (search) automated brain fluid management system. The device integrates proprietary hardware and software to achieve continuous brain pressure measurement and closed-loop, gravity-driven, precision drainage of brain fluid to personalized volume or pressure goals.
Clinical Applications and Patient Population
The Intellidrop (search) is indicated to provide external drainage of cerebrospinal fluid (search) (CSF) and monitoring of CSF drainage and intracranial pressure (search) (ICP) for ventricular or lumbar use. The system addresses critical needs for patients with traumatic brain injury (search) (TBI), stroke (search), skull base tumor (search) surgeries, and neurodegenerative conditions like normal pressure hydrocephalus (search).
"We've heard from hundreds of ICU nurses that automating external CSF clearance is going to be a huge relief for nurses and a better experience for patients with Traumatic Brain Injury (search) (TBI), Stroke (search), skull base tumor (search) surgeries, neurodegenerative conditions like Normal Pressure Hydrocephalus (search) and more," said Caitlin Morse, BrainSpace (search) CEO and co-founder. "That hope can now become a reality in hospitals around the US with Intellidrop (search) FDA cleared."
Market Need and Global Impact
According to a recent Lancet study cited by BrainSpace (search), 1 in 3 people on the planet will face neuro injury, illness or degeneration in their lifetime, representing 2.5 billion people globally who could benefit from improved neurological care solutions. The company emphasizes that "Time is Brain," noting that earlier access to appropriate care reduces the risk that brain injury results in severe life-long disability.
Technology and Innovation
The Intellidrop (search) represents part of an emerging category of Brain Fluid Interface (BFI) products that measure, monitor and act upon brain fluids including cerebrospinal fluid (search), interstitial fluid, and cerebral blood. These BFI devices provide a continuous window into brain health and generate novel, multimodal, contextualized data that is key to training Physical AI models.
Workflow Benefits and Healthcare Impact
Automating brain pressure management simplifies workflow for hospitals and staff, which BrainSpace (search) believes will make care more accessible and allow clinicians to introduce more personalized approaches. The system addresses ICU nursing shortages by reducing the manual intervention required for external CSF clearance procedures.
BrainSpace (search) was founded in 2021 and has received recognition as a past winner of the Seattle Angel Conference and Flywheel Investment Conference, and was a grand finalist in MedTech Innovator 2024. The company believes BFI technology holds the potential to drive patient benefit across the spectrum of neurological diseases at every age.